Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT05393284 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy

Interventions

DRUG: OPL-0401 Dose 1
DRUG: Placebo

Sponsor

Valo Health, Inc.